An FDA panel backs Moderna's mRNA flu shot, against the agency's own drift

A unanimous vote that points the other way

An FDA advisory committee voted unanimously to recommend approval of Moderna's mRNA seasonal influenza vaccine, the story reports, after a stretch of internal turmoil the headline calls 'agency drama.' The drama, as commenters lay it out, centers on Vinay Prasad, an FDA official whom critics describe as vaccine-skeptical and who was seen as slowing the process. The structure of the moment is what makes it notable: a panel of outside experts recommending approval despite leadership that some viewed as hostile to it.

The substance is easy to lose. This is not a COVID shot or a general verdict on mRNA. It is a seasonal flu vaccine, and the case for the platform is timing. Traditional flu shots require a months-ahead guess about which strains will dominate, because culturing them is slow. An mRNA flu vaccine can in principle be formulated later, letting the educated guess land closer to flu season and, the argument goes, more accurately. The exact vote tally, Prasad's precise title, and the dates here come from commenters rather than a verified source read, so the framing stays careful.

The most useful early correction was simply about the headline:

"For context, it's a seasonal flu vaccine, the title is a bit unclear." — a commenter untangling the headline

Then the conversation widened past the man. One commenter supplied a second data point and used it to reframe the whole problem:

"Prasad was also behind the rejection of a closely watched gene therapy for Huntington's disease made by UniQure … It's the entire organizational structure that puts him, or any other one person, in the position that they have the power to do this." — a commenter shifting blame to the structure

The single-point veto, not the person, becomes the target. Others pushed back on the 'science denier' framing entirely, defending the official's methodological record:

"If Prasad says it needs more and better data I'd put money on it needing it." — a commenter vouching for his track record

And one reader aimed the skepticism at the reporting itself:

"Flu vaccines aren't immunizing vaccines. They protect against specific strains, and half the time they immunize against a strain that doesn't become widespread … This article has no data about why mRNA flu vaccines will improve these outcomes" — a commenter faulting the article's missing evidence

What holds the thread together is that none of these positions require choosing a political side. A panel can endorse a vaccine, a skeptic can have a real methodological point, the institutional design can still be the deeper flaw, and the write-up can still be thin on numbers — all at once. The unanimous vote is the headline; the structure that made it surprising is the story.